Compare Charles River Laboratories Intl. Inc (CRL) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Sprott Uranium Miners ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $285.69 (market cap $13.46B), while Sprott Uranium Miners ETF trades at $55.4. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| CRL | URNM | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $282.00 | $83.99 |
52-Week Low | $145.57 | $44.14 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
URNM trades at $55.50, up 1.65% today, with a bullish technical signal driven by moving averages. Recent news highlights strong nuclear sector tailwinds from AI power demand and government funding, though some articles question miner valuations. Support and resistance cluster tightly around $55-56, indicating potential volatility.
The outlook is positive given nuclear energy's role in AI infrastructure, but risks include uranium price volatility and concentrated miner exposure. Analyst sentiment is mixed, with debates over supply chain positioning versus pure uranium price leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
